Leustatin (Cladribine)

Cladribine is a purine nucleoside analog that enters cells and is phosphorylated to its active triphosphate form. This metabolite incorporates into DNA during replication, causing strand breaks and preventing DNA repair. The resulting DNA damage triggers apoptosis preferentially in proliferating lymphocytes, leading to selective depletion of B‑ and T‑cells that drive autoimmune activity or malignancy.

The dosing schedule for Leustatin is determined by the prescribing physician based on the specific indication, patient weight, renal and hepatic function, and treatment protocol. Clinicians calculate the appropriate intravenous dose and administration intervals, and the regimen may be adjusted during the course of therapy according to laboratory monitoring and clinical response.

The safety of cladribine in pregnancy and lactation has not been established. It is generally contraindicated in pregnant women because of potential fetal toxicity, and breastfeeding is not recommended during treatment and for a period after the last dose. Women of childbearing potential should use effective contraception throughout therapy and for a defined time afterward.

To request Leustatin, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if required—and assistance with import documentation.

Compared with other disease‑modifying therapies for multiple sclerosis, cladribine offers a short‑course oral or intravenous regimen that provides long‑lasting immune modulation after limited dosing cycles. Unlike continuous‑infusion agents, it requires fewer treatment visits, but it carries a distinct safety profile, including lymphopenia and infection risk, which must be weighed against efficacy and patient preference.

Leustatin should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). The vial must be kept in its original packaging to protect it from light, and it should never be frozen or shaken. If temperature excursions occur, the product should be inspected for visual changes before use.

Leustatin is supplied as an intravenous solution that is administered by a qualified healthcare professional. The infusion is typically given over a specified period, often ranging from several minutes to an hour, depending on the prescribed dose and clinical protocol. Venous access should be established, and the patient monitored for infusion‑related reactions throughout the administration.

The most serious risks of cladribine therapy include profound lymphopenia leading to opportunistic infections such as pneumocystis jirovecii pneumonia, reactivation of latent viruses, and rare but severe autoimmune disorders like hepatitis or thyroiditis. Additionally, rare cutaneous reactions such as Stevens‑Johnson syndrome and potential secondary malignancies have been reported, requiring vigilant monitoring.

Leustatin is contraindicated in patients with active severe infections, known hypersensitivity to cladribine or any excipients, pregnant or breastfeeding women, and individuals with significant hepatic or renal impairment unless a specialist determines a safe benefit‑risk balance. It should also be avoided in patients receiving live vaccines or other potent immunosuppressive agents without careful clinical oversight.